Navigation Links
AEterna in Medical News

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

...survival and secondary endpoints include overall response rate, overall survival and safety. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. in the United States, Canada and Mexico. About Multiple Myeloma Multiple myeloma, a cancer of the plasma cell, is an incura...

Generic Erosion of Established Agents Will Offset Growth From Uptake of Emerging Therapies in the Market for Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms

...eride fixed-dose combination Duodart will likely increase compliance, while aeterna Zentaris/Sanofi-Aventis/Shionogi's cetrorelix and aeterna Zentaris/Spectrum Pharmaceuticals/Nippon Kayaku's ozarelix both aim to redu...

Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System

...c partnership with sanofi-aventis in Korea and, moreover, have 20 other partners focusing on innovative products, including CSL, Solvay, Actelion, and aeterna Zentaris among others. HANDOK is the leader in diabetes treatment in Korea. It is also known to have leading expertise in various therapeutic categori...

AEterna Zentaris Reports First Quarter 2009 Financial and Operating Results

...s QUEBEC CITY, May 6 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ) ("the Co... BPH in the U.S. Juergen Engel, Ph.D., aeterna Zentaris' President and Chief Executive Officer co...nior Vice President and Chief Financial Officer of aeterna Zentaris added, "The recent partnership with sanof...

Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology

...s, including stable disease, have been treated for various durations up to more than three years. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals i...

AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

... QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global...Senior Vice President and Chief Medical Officer at aeterna Zentaris. The safety study titled, "Cetrorelix p...events. About Cetrorelix Cetrorelix is part of aeterna Zentaris' LHRH antagonist therapeutic approach tha...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...) Enabling Technologies Index (HHV) Drop Hillenbrand Industries (NYSE: HB ) Add Eurand N.V. (Nasdaq: EURX ) GI/Gender Index (HHU) Drop aeterna Zentaris (Nasdaq: AEZS ) King Pharmaceuticals (NYSE: KG ) Nastech Pharmaceutical (Nasdaq: NSTK ) Add Columbia Laboratories Inc. (Nasdaq: CB...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia

...e disease, have been treated for months to almost 3 years, on both the daily and weekly schedule. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, ...

Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology

...le disease, have been treated for months to almost 3 years, on both the daily and weekly schedule. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Malignant Gliomas The American Cancer Society estimates tha...

AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007

... QUEBEC CITY, Oct. 31 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global b... Company's website for a period of 30 days. About aeterna Zentaris Inc. aeterna Zentaris Inc. is a global biopharmaceutical compan...
AEterna in Medical Technology

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

...isease. A minimum of 4 and a maximum of 24 patients will be required to complete the study. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. in the United States, Canada and Mexico. About Recurrent Pediatric Tumors Approximately 12,400 children and adolesc...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... http://www.asco.org/ . A copy of the poster may be obtained by contacting the Company. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Colon Cancer According to the American Cancer Society...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

...urvival still has not been reached now at 17 months. Nine patients remain on active treatment. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceut...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

...uding stable disease, have been treated for various durations up to more than three years. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Keryx Biopharmaceuticals, Inc. Keryx Bioph...

AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108

... QUEBEC CITY, Oct. 2 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global...ent." Juergen Engel, Ph.D., President and CEO of aeterna Zentaris stated, "These results confirm the early ...e: Annals of Oncology 15:1149-1150, 2004). About aeterna Zentaris Inc. ...

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

...s, including stable disease, have been treated for various durations up to more than three years. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals i...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

...s, including stable disease, have been treated for various durations up to more than three years. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals i...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

... Executive Officer. New Board Member. In November 2007, Paul Blake, M.B., currently Senior Vice President and Chief Medical Officer of aeterna Zentaris Inc., joined Memory Pharmaceuticals' Board of Directors. Dr. Blake has over 27 years of clinical development experience, including...

Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology

...e disease, have been treated for months to almost 3 years, on both the daily and weekly schedule. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, ...

Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium

...le disease, have been treated for months to almost 3 years, on both the daily and weekly schedule. KRX-0401 (perifosine) is in-licensed by Keryx from aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: AEZ) in the United States, Canada and Mexico. About Renal Cell Carcinoma In 2007, an estimated 51,000 new cases...

More>>

AEterna in Biological Technology

AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference

... QUEBEC CITY, Aug. 6 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a globa...e webcast of the presentation will be available on aeterna Zentaris' website at www.aezsinc.com in the Inve...od of 30 days on the Company's website. About aeterna Zentaris Inc. ...

AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009

... QUEBEC CITY, Aug. 5 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a globa...pany's website for a period of 30 days. About aeterna Zentaris Inc. aeterna Zentaris Inc. is a global biopharmaceutical compan...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

... QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), ("the C..., Ph. D., President and Chief Executive Officer of aeterna Zentaris commented, "We are very pleased and excit...oryInformation/Guidances/ucm080571.pdf About aeterna Zentaris Inc. ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...che players worldwide such as Abbott Laboratories, aeterna Zentaris Inc., ALZA Corporation, Amgen Inc., Astra...A to Conduct Phase I Trial of PRX302 II-63 aeterna Zentaris's Ozarelix Phase II Trial Shows Positive ...ains FDA Approval for Finasteride's ANDA II-79 aeterna Zentaris Enters into Agreement with Nippon Kayaku ...

AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction

... QUEBEC CITY, July 7 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a globa...Sciences (PNAS), of new data supporting the use of aeterna Zentaris' ghrelin receptor antagonist compound, AE...in alcoholic patients). The work, coordinated by aeterna Zentaris, emerged from an international collaborat...

AEterna Zentaris Receives US$10 Million from Institutional Investors

... QUEBEC CITY, June 24 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a globa...chase warrants to certain institutional investors. aeterna Zentaris received net proceeds of approximately US... Dr. Juergen Engel, Ph. D., President and CEO of aeterna Zentaris stated, "We are very pleased with this vo...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

... QUEBEC CITY, June 15 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a globa...Senior Vice President and Chief Medical Officer of aeterna Zentaris. The safety study (041) titled, "Cetror...9 with an NDA filing targeted in 2010. Recently, aeterna Zentaris also announced that patients completing t...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

... QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a globa...entered into a previously announced agreement with aeterna Zentaris for the development, registration and mar...this collaboration between sanofi-aventis U.S. and aeterna Zentaris, patients completing two years of therapy...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

... QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a globa...Senior Vice President and Chief Medical Officer at aeterna Zentaris,"In light of these neutral results and an...one in relapsed and refractory myeloma. About aeterna Zentaris Inc. ...

AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130

... QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - aeterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a globa...," said Juergen Engel, Ph.D., President and CEO of aeterna Zentaris. "Our product portfolio is now complement...n Convention Center, in Washington, DC. About aeterna Zentaris Inc. ...
Other Tags
(Date:10/20/2014)... hc1.com today announced the launch ... that enables healthcare organizations of all sizes to ... relationship management (“CRM”) solution. , Designed from the ... the healthcare industry, the hc1 Healthcare Relationship Cloud™ ... by combining healthcare CRM, HIPAA-compliant collaboration, and real-time ...
(Date:10/20/2014)... Angeles, CA (PRWEB) October 20, 2014 ... fitness expertise, nutritional coaching, corporate wellness programming, authorship, international ... CPT, is excited to announce the release of the ... , After many years of coaching thousands of individuals ... nutrition tracking app that does not require calorie counting ...
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Voicheck as Assistant Director of their CentralSource ... in managing the innovative turnkey drug sourcing, distribution, ... Matthew brings over 12 years of industry experience, ... Myoderm at the peak of their international success ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
(Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
Other Contents